Amos Katz, MD
Neurology · Eatontown, NJNPI 1952411340
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $428,230 of the $557,960 with a category attached, or 76.7%. It is spread thinly across 34 manufacturers, the largest accounting for just 23.1%. Reporting peaked in 2019 at $140,750 and has fallen 67.4% since, to $45,884 in 2025. Among neurology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,522 payments — averaging $366.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$129K
- E.r. Squibb & Sons, L.L.C.$81K
- TG Therapeutics, Inc.$75K
- Genentech USA, Inc.$63K
- Sanofi$60K
- Novartis$58K
- plus $93K from 28 others
Across 20 payments — averaging $32,999 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$643K
- Biogen$13K
- Sanofi$4K
What the payments were for
- Consulting fees$68,34112%
- Speaking & faculty fees$428,23077%
- Travel & lodging$35,7626%
- Food & beverage$25,4495%
- Education$1800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 260 | $129,070 |
| E.r. Squibb & Sons, L.L.C. | 75 | $80,614 |
| TG Therapeutics, Inc. | 81 | $75,155 |
| Genentech USA, Inc. | 131 | $63,015 |
| Sanofi | 108 | $59,886 |
| Novartis | 257 | $57,570 |
| Bristol Myers Squibb | 115 | $30,461 |
| AbbVie(2 entities) | 149 | $29,269 |
| Johnson & Johnson | 77 | $13,502 |
| EMD Serono, Inc. | 118 | $7,641 |
| AstraZeneca | 30 | $4,637 |
| Amgen(2 entities) | 24 | $4,632 |
| Banner Life Sciences, LLC | 2 | $817 |
| Avanir Pharmaceuticals, Inc. | 14 | $307 |
| Teva Pharmaceuticals USA, Inc. | 17 | $202 |
| Mallinckrodt Hospital Products Inc. | 11 | $164 |
| Otsuka America Pharmaceutical, Inc. | 3 | $153 |
| Lundbeck LLC | 10 | $148 |
| Biohaven Pharmaceuticals, Inc. | 3 | $132 |
| Mallinckrodt Enterprises LLC | 6 | $82 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $57 |
| Ipsen Biopharmaceuticals, Inc | 4 | $56 |
| Insulet Corporation | 2 | $54 |
| Pfizer | 3 | $52 |
| Merz Pharmaceuticals, LLC | 3 | $50 |
| Vanda Pharmaceuticals Inc. | 3 | $48 |
| ANI Pharmaceuticals, Inc. | 3 | $47 |
| Medtronic(2 entities) | 2 | $41 |
| Acorda Therapeutics, Inc | 2 | $27 |
| Sequel Med Tech, LLC | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Cycle Pharmaceuticals Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$557,960 in reported general payments places this provider in the 95th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MayzentSiponimod | 44 | $471,232 |
| ZeposiaOzanimod Hydrochloride | 35 | $431,610 |
| AubagioTeriflunomide | 23 | $250,990 |
| VumerityDiroximel Fumarate | 21 | $199,825 |
| Teriflunomide | 29 | $114,138 |
| CopaxoneGlatiramer Acetate | 11 | $61,817 |
| Dalfampridine ErDalfampridine | 41 | $14,706 |
| MyrbetriqMirabegron | 15 | $7,643 |
| Modafinil | 39 | $3,396 |
| Baclofen | 124 | $3,003 |
| Fentanyl | 11 | $1,684 |
| Gabapentin | 47 | $1,176 |
| Duloxetine Hcl | 24 | $582 |
| Oxybutynin Chloride ErOxybutynin Chloride | 12 | $559 |
| Tizanidine Hcl | 29 | $544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisMayzent | $57,570 | $471,23244 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $80,614 | $431,61035 claims |
| SanofiAubagio | $59,886 | $250,99023 claims |
| BiogenVumerity | $129,070 | $199,82521 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $202 | $61,81711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 521 neurology providers in New Jersey.
Other neurology in Eatontown
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
- Mario VukicHackensack$310K
- Andrew SylvesterBridgewater$296K
- Donald BaroneCamden$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.